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Abstract
Background: Mitochondrial diabetes is a kind of rare diabetes caused by monogenic mutation in mitochondia. The
study aimed to summarize the clinical phenotype profiles in mitochondrial diabetes withm.3243A>G mitochondrial
DNA mutation and to investigate the mechanism in this kind of diabetes by analyzing the relationship among
clinical phenotypes and peripheral leukocyte DNA telomere length.
Methods: Fifteen patients with maternally inherited diabetes in five families were confirmed as carrying the
m.3243A>G mitochondrial DNA mutation. One hundred patients with type 2 diabetes and one hundred healthy
control subjects were recruited to participate in the study. Sanger sequencing was used to detect the m.3243A>G
mitochondrial DNA mutation. The peak height G/A ratio in the sequence diagram was calculated. Real-time
polymerase chain reaction (PCR) was used to measure telomere length.
Results: The patients with mitochondrial diabetes all had definite maternally inherited history, normal BMI
(19.5 ± 2.36 kg/m2), early onset of diabetes (35.0 ± 14.6 years) and deafness. The peak height G/A ratio
correlated significantly and negatively with the age at onset of diabetes (≦25 years, 61.6 ± 20.17 %; 25–45
years, 16.59 ± 8.64 %; >45 years, 6.37 ± 0.59 %; p = 0.000). Telomere length was significantly shorter among
patients with mitochondrial diabetes and type 2 diabetes than in the control group (1.28 ± 0.54 vs. 1.14 ± 0.43
vs. 1.63 ± 0.61; p = 0.000). However, there was no significant difference between patients with mitochondrial
diabetes and those with type 2 diabetes. There was no correlation between telomere length and the peak
height G/A ratio.
Conclusion: Deafness with definite maternal inheritance and normal BMI, associated with elevated blood
lactic acid and encephalomyopathy, for the most part, suggest the diagnosis of mitochondrial diabetes . The
peak height G/A ratio could reflect the spectrum of age at onset of the disease. Telomere length was shorter
in patients with mitochondrial diabetes and those with type 2 diabetes, which suggests that the shorter
telomere length is likely involved in the pathogenesis of diabetes but is not specific for this kind of diabetes.
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Background
Mitochondrial diabetes is a kind of rare diabetes caused
by monogenic mutation in mitochondria, which was first
described in 1992, results from an A to G substitution at
nucleotide position 3243 (m.3243A>G mitochondrial
DNA mutation) of the mitochondrial gene encoding
tRNALeu [1–4]. Eighty-five percent of mitochondrial dia-
betes cases are associated with m.3243A>G mitochondrial
DNA mutation [5], and although other mitochondrial
DNA point mutations have been associated with mito-
chondrial diabetes, these occurrences are extremely rare
[6]. Because mitochondria are distinct organelles in the
cytoplasm, its inheritance is only maternal, and mitochon-
drial DNA mutations have different heteroplasmy levels
that vary among different tissues in a single individual;
hence, there is a wide range of clinical phenotypes and
mitochondrial diabetes is frequently misdiagnosed as ei-
ther type 1 or type 2 diabetes, depending on the clinical
presentation [5].
DNA telomeres, which are specific DNA-protein
structures in the terminal regions of chromosomes, are a
biomarker of biological aging and can reflect the lifespan
of cells [7]. Telomere shortening has been observed in
subjects with type 2 diabetes or impaired glucose toler-
ance, for example, in Chinese [8], Afro-Caribbean [9],
Arabic and Caucasian [10] populations. Many factors are
involved in telomere shortening; for instance, reactive
oxidative species (ROS) as by-products of mitochondrial
oxidative phosphorylation (OXPHOS) play an important
role in telomere shortening [11–13]. Mutations in mito-
chondrial DNA have an impact on the mitochondrial
function of the pancreas among patients with mitochon-
drial diabetes. However, whether the change in the mito-
chondrial function in patients with mitochondrial
diabetes can affect DNA telomere length is still un-
known. In this study, we hypothesize that telomere
length shortening exists in the beta cells of mitochon-
drial diabetes, which can shorten the lifespan of beta
cells. Exploring the pathogenesis by investigating the re-
lationship between changes in mitochondrial function
and telomere length can provide new insight.
The present study aimed to summarize the profiles of
clinical phenotypes in fifteen patients with mitochondrial
diabetes from five different families and to investigate
the mechanism of mitochondrial diabetes by analyzing
the relationship among clinical phenotypes and periph-
eral leukocyte DNA telomere length in blood.
Methods
Study subjects
According to the inclusion criteria for this study, forty
subjects with diabetes in Peking Union Medical College
were included between 2007 and 2014. The inclusion
criteria were as follows: ① age at the diagnosis of
diabetes ≤ 40 years old; ② BMI ≤ 24 kg/m2; ③ negative
autoimmune diabetes antibodies: insulin autoantibody
IAA (−), islet cell antibody ICA (−), glutamate decarb-
oxylase antibody GAD (−), and protein-tyrosine-
phosphatase antibody IA2 (−); ④ maternal family history
of diabetes; ⑤ deafness; ⑥ elevated serum lactic acid
level; and ⑦ encephalomyopathy. Items ①,②,③,④are
necessary items, with or without items ⑤,⑥,⑦. Five pa-
tients were confirmed as carrying the m.3243A>G
mitochondrial DNA mutation, these patients were de-
fined as mitochondrial diabetes. By further screening
the family members of the five probands, a total of fif-
teen patients with mitochondrial diabetes (age range:
17 ~ 68 years-old) were confirmed. One hundred patients
with type 2 diabetes (age range: 22 ~ 67 years-old)
and one hundred healthy individuals without diabetes
(age range: 19 ~ 65 years-old) were recruited to participate
in the study and were matched according to age and
gender. The study protocol was approved by the Ethics
Committee of Peking Union Medical College Hospital.
The subjects signed an informed consent form and all the
subjects provided written informed consent for the publi-
cation of their clinical details. We also obtained the writ-
ten informed consent from the guardians of the only one
subjects who was 17 years-old. The study protocol was
approved by the Ethics Committee of Peking Union
Medical College Hospital.
M.3243A>G mitochondrial DNA mutation screening
method
Genomic DNA from peripheral lymphocytes was iso-
lated using the QIAamp DNA Mini Kit (QIAGEN,
Germany). The PCR assay was designed to detect the mt
3243A to G mutation using a direct PCR. The following
two primers were used in one reaction tube:
Forward: 5′-AGCGCCTTCCCCCGTAAATGA-3′,
Reverse: 5′-AGAATGATGGCTAGGGTGACTTC-3′.
The primers were designed using Oligo 6.0. Nucleo-
tides 3160–3620 of mt DNA were amplified. Each PCR
product was segregated using agarose gel electrophoresis
and purified using the gel extraction method before be-
ing sequenced in an ABI3730xl sequencer using the for-
ward PCR primer. The sequencing data were aligned
using BLAST Search Genome (http://genome.ucsc.edu).
Each sample was sequenced twice.
The peak height G/A ratio in the sequence diagram
The peak height G/A ratio in the sequence diagram was
calculated according to the mean value of the sequences
(Each sample was sequenced twice). The peak height G/A
ratio was defined as the peak height A was divided by the
peak height G as show in Fig. 1.
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Leukocyte DNA telomere length measurement
Telomere length was determined as the relative ratio of
telomere repeat copy number to the single copy number
(T/S) using the novel monochrome multiplex quantita-
tive PCR protocol described by Cawthon [14]. Telomere





and albumin was employed as the single copy gene
reference using primers modified with the addition of





The reagent components and final concentrations
were 900 nM each primer (IDT), 1 × AmpliTaq Buffer II,
3 mM MgCl2, 0.2 mM per dNTP, 1 mM DTT, 1 M beta-
ine, 0.75 × SYBR Green I and 0.625U AmpliTaq Gold
DNA polymerase. Human genomic DNA samples, 5 ng
to 70 ng, were used to generate two standard curves for
each PCR plate (five concentrations with a high level of
150 ng and a low level of 1.85 ng per reaction). Thermal
cycling: 1 cycle of 15 min at 95 °C; 2 cycles of 15 s at
94 °C, 15 s at 49 °C; and 32 cycles of 15 s at 94 °C, 10 s
at 62 °C, 15 s at 74 °C with signal acquisition, 10 s at
84 °C, and 15 s at 88 °C with signal acquisition. Bio-Rad
CFX Manger software automatically estimated the value
for each sample T (telomere) and S(single copy gene)
using standard curve. Standard curve efficiencies for
both primer sets were above 90 %, and regression coeffi-
cients were at least 0.99 in all PCR runs. The within-plate
and between-plate % coefficient of variation(% CV), which
is based on the ratio of the standard deviation across
replicates to the mean, were 18 % and 7 %, respectively.
For study samples, the with-plate % CV ranged from
8.2–14.3 %.
Statistical analyses
The statistical analyses were performed using SPSS 17.0.
Parameters not normally distributed were transformed.
The variables were expressed as the mean ± SD. Statis-
tical analyses were performed with ANOVA followed by
Bonferroni’s post hoc pairwise comparisons. The multi-
variable linear regression analysis was used to test the
relationship between variables and the risk factors.
Results
1. Clinical features in mitochondrial diabetes
Five patients with mitochondrial diabetes from five
different families were confirmed by m.3243A>G
mitochondrial DNA mutation screening from forty
suspected patients with mitochondrial diabetes;
screening rate was 12.5 %. In the other maternal
members of the five patients from the five families,
there were eleven subjects with m.3243A>G
mitochondrial DNA mutation among the eleven
subjects, ten subjects suffered from mitochondrial
diabetes, only one subject had mutation without any
clinical presentation. Therefore, in total, there were
fifteen patients with mitochondrial diabetes in the
five families (Fig. 2). The mean age at the diagnosis
of diabetes the five probands was 23.1 ± 8.2 years,
and the onset of impaired hearing loss was before
the diagnosis of diabetes. The five probands were all
female; two of them had oligomenorrhea, their follicle
stimulating hormone(FSH) and luteinizing
hormone(LH)level was below the normal range
(Table 1). At the onset of mitochondrial diabetes, the
mean age of the fifteen patients was 35.0 ± 14.6 years,
their BMI was 19.5 ± 2.36(kg/m2), and one patient
presented acutely with ketoacidosis-related type 1
diabetes, while the others presented insidiously with
symptoms similar to type 2 diabetes. The general and
specific clinical features of the 15 patients with
mitochondrial diabetes are shown in Tables 2 and 3,
respectively.
2. Comparison of telomere length among patients
with mitochondrial diabetes and type 2 diabetes
and healthy controls
The ages were matched among the three groups,
and the duration of diabetes was matched between
those with mitochondrial diabetes and those with
type 2 diabetes. There was a significant difference in
BMI among the three groups. Peripheral blood
leukocyte DNA telomere length was significantly
shorter in patients with mitochondrial diabetes and
Fig. 1 The peak height G/A ratio was defined as the peak height A
was devided by the peak height G
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type 2 diabetes than in healthy controls; however,
there was no significant difference between those
with mitochondrial diabetes and those with type 2
diabetes (Table 4).
3. Correlation analysis between m.3243A>G
mitochondrial DNA mutation (the peak height
G/A ratio) and onset age of mitochondrial diabetes
The peak height G/A ratio in the sequence diagram
was calculated. The peak height G/A ratio was
significantly different according to the age at the
diagnosis of diabetes (≤25 years, 25–45 years, and
>45 years) (Table 5) and was negatively associated
with the age at the diagnosis of diabetes after
adjusting the age, BMI (r = −0.891; p < 0.001).
4. Correlation between telomere length and
m.3243A>G mitochondrial DNA mutation
(the peak height G/A ratio) and diabetes-related
parameters
There was no significant relationship between
peripheral blood leukocyte DNA telomere length
and the peak height G/A ratio after adjusting age
fasting glucose, insulin, C-peptide, HbA1c,
HOMA-IR, and HOMA-IS. Fasting glucose, insulin,
C-peptide, HbA1c, HOMA-IR, and HOMA-IS were
not significantly related to DNA telomere length
(Table 6).
Fig. 2 a Pedigree of family I. b Pedigree of family II. c Pedigree of family III. d Pedigree of family IV. e Pedigree of family V. Show the
patient with maternally inherited diabetes and deafness, Show family member without the disease. Shows the proband in the family.
II1 in family II and II1 in family IV have MELAS and mitochondrial diabetes. III1 in family II has mt DNA 3243 mutation, although he did not have
symptoms of mitochondrial diabetes
Table 1 Blood gonadal hormone levels in 2 patients with













III1 (P:I) 18 17.4 5.5 3.9 1.7 355.25
II1 (P:III) 26 21.7 1.2 0.21 3 28.7
P I-V represent family I-V, Age age at onset of oligomenorrhea, FSH follicle
stimulating hormone, LH luteinizing hormone, T testosterone, E2 estradiol
Table 2 General clinical features of mitochondrial diabetes
Mitochondrial diabetes (n = 15)
Age (year) 35.0 ± 14.6
Gender (F/M) 12:3
Disease Duration (year) 4.00 ± 2.54
BMI (kg/m2) 19.5 ± 2.36
HbA1c (%) 6.42 ± 1.01
Fasting blood glucose (mmol/L) 7.75 ± 2.03
Fasting insulin (μIU/ml) 5.23 ± 3.26
Fasting C-peptide (ng/ml) 0.53 ± 0.37
HOMA-IR 1.63 ± 0.81
HOMA-IS 0.03 ± 0.02
Diabetes treatment 7:8
(Insulin: oral hypoglycemic medication) (5 probands all received
insulin therapy)
BMI body mass index, HOMA-IR fasting plasma glucose (mmol/L) *fasting
insulin (μIU/ml)/22.5, HOMA-IS 1/fasting plasma glucose (mmol/L) *fasting
insulin (μIU/ml)
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Discussion
Patients with mitochondrial diabetes generally exhibit
heteroplasmy levels of between 1 % and 40 % with re-
gard to m.3243A>G mitochondrial DNA mutation in the
blood [6]; however, heteroplasmy levels may vary in dif-
ferent tissues in a single individual. Although blood gen-
erally contains the lowest heteroplasmy levels [15, 16],
detecting m.3243A>G mitochondrial DNA mutation in
blood is used as a simple and widely available screening
method. The present study screened m.3243A>G
mitochondrial DNA mutation in forty patients with
suspected mitochondrial diabetes, five patients were
confirmed to have the disease; the screening rate was
12.5 %, which was considerably higher than 1.69 %
(the screening rate in patients diagnosed with type 2
diabetes, as reported by Xiang et al. [17]). This result
suggested that targeted screening in patients with sus-
pected mitochondrial diabetes (combined with early
onset of diabetes and normal BMI) could improve the
diagnosis of mitochondrial diabetes.
Mitochondrial diabetes is frequently misdiagnosed as
either type 1 or type 2 diabetes depending on the age of
the patients and the mode of presentation. In the
present study, patients with mitochondrial diabetes had
a definite maternal history of diabetes; four out of five
probands represented the second or third generation
with diabetes in the family, which suggests that maternal
history of diabetes plays an important role in the diagno-
sis. The mean age at the onset of diabetes was 35 years-
old, ranging from 17 years to 68 years; however, the age
at onset for the proband in each family was relatively
young, with normal BMI, accompanied by different de-
grees of deafness in the high-frequency domain. In the
study, all the patients with mitochondrial diabetes carrying
m.3243A>G mitochondrial DNA mutation had deafness,
suggesting the strong association between mitochondrial
diabetes and hearing loss, which was in accordance with
Mancuso M, et al. [18]. Several female patients had oligo-
menorrhea caused by idiopathic hypogonadotropic hypo-
gonadism, which suggests that mitochondria dysfunction
could be involved in pituitary function, leading to idio-
pathic hypogonadotropic hypogonadism. In this study,
even in the same family, the clinical presentations were
different; the progress of diabetes was not consistent;
Table 3 Specific clinical features in mitochondrial diabetes (n = 15)








Encephalomyopathy The peak height
G/A ratio%
1 II1 (P:I) 68 18.4 ND + ND - 5.9
2 II2 49 23.4 IAA (−)、ICA (−)、GAD (−) + ND - 14
3 II4 48 16.8 IAA (−)、ICA (−)、GAD (−) + ND - 14.9
4 III1 18 18.7 IAA (−)、ICA (−)、GAD (−) + - - 83.3
5 I2 (P:II) 25 17.4 ND + ND - 31.6
6 II1 31 21.2 ND + + + 29.1
7 II2 43 20.1 ND + ND - 8.2
8 II3 38 19 IAA (−)、ICA (−)、GAD (−) + ND - 27.6
9 I2 (P:III) 43 18.4 ND + ND - 8
10 II1 17 18.3 IAA (−)、ICA (−)、GAD (−) + ND - 65
11 I2 (P:IV) 33 16.7 IAA (−)、ICA (−)、GAD (−) + - - 29
12 II1 24 21.7 ND + + + 27.1
13 II1 (P:V) 26 24.9 ND + ND - 34.5
14 II2 46 19.1 ND + ND - 15.2
15 III1 17 18.4 IAA (−)、ICA (−)、GAD (−) + ND - 63.6
For the structure of the five- mitochondrial diabetes pedigree, see Fig. 1. P, I-V represent family I-V.;ND represents undetected;-, negative; +, positive. The peak
height G/A ratio, m.3243A>G mitochondrial DNA mutation peak height G to A ratio
Table 4 Comparison of age, duration of diabetes, BMI, and telomere length
Mitochondrial diabetes (n = 15) T2DM (n = 100) Healthy controls (n = 100) P
Age (year) 35.2 ± 19.1 42.2 ± 14.3 38.3 ± 10.3 0.070
Duration of diabetes (year) 4.0 ± 2.7 4.8 ± 3.5 —— 0.440
BMI (kg/m2) 19.5 ± 2.36 24.3 ± 2.4 21.2 ± 1.4 0.000***
Telomere length 1.28 ± 0.54 1.14 ± 0.43 1.63 ± 0.61 0.000***
***p < 0.001. There was a significant difference in BMI and telomere length among the three groups
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several patients presented acutely with ketoacidosis-
related type 1 diabetes; and other patients presented
insidiously with symptoms similar to type 2 diabetes.
Although siblings in the same families had the same
m.3243A>G mitochondrial DNA mutation, the clinical
manifestations were different. In family II, the sister
presented with diabetes and deafness, whereas the
brother had diabetes and deafness and also presented
with MELAS (mitochondrial encephalomyopathy with
lactic acidosis and stroke-related episodes). Therefore,
to properly diagnose mitochondrial diabetes, under-
standing the profiles of the clinical presentations of
the disease is very important.
Heteroplasmy levels lead to varying clinical pheno-
types in different tissues [19, 20]. In patients with mito-
chondrial diabetes, mitochondrial dysfunction in beta
cells causes insulin secretion disorder [21, 22], imbalance
of ion concentrations, and cell death within the vascular
stria that leads to reduction in sound transduction [23].
Direct PCR and sequencing analysis (Sanger sequencing)
are widely available and simple methods for detecting
m.3243A>G mitochondrial DNA mutation. Although
the peak height G to A ratio does not represent the real
value of heteroplasmy levels, it is widely used for detect-
ing point mutation in disease diagnosis. This study
found that the peak height G to A ratio was negatively
associated with age at the onset of mitochondrial dia-
betes, that the ratio was higher, and that age at the onset
of the disease was younger. The peak height G to A ratio
depended on m.3243A>G mitochondrial DNA mutation
heteroplasmy levels, according to the research con-
ducted by Laloi-Michelin et al. [23]. The results sug-
gested that although Sanger sequencing is not a
quantitative method compared with site-specific quan-
titative PCR, it could be a simple method for indicating,
to some extent, the degree of severity of mitochondrial
diabetes in clinical work.
Different m.3243A>G mitochondrial DNA mutation
heteroplasmy levels result in varying energy metabolism
disorders of mitochondria [24]. The mechanism of dia-
betes is complicated. Mitochondrial diabetes caused by
monogenic mutation is an ideal model for investigating
the pathogenesis of diabetes. Mitochondria, which are
an essential component of energy production through
oxidative phosphorylation (OXPHOS), have a close rela-
tionship with cellular senescence. Mitochondria generate
a large amount of reactive oxidative species (ROS) as a
toxic by-product of OXPHOS, which plays an important
role in telomere shortening [25]. Mitochondrial dysfunc-
tion caused by DNA mutations is observed in mitochon-
drial dysfunction in the pancreas has an impact on beta
cell secretion function in patients with mitochondrial
diabetes [21, 22]. Telomere length can most likely be as-
sociated with the lifespan of beta cells, which is related
to the secretion function of beta cells. To the best of our
knowledge, this study is the first to investigate telomere
length in patients with mitochondrial diabetes. This
study found that compared with healthy controls, telo-
mere length was shorter in patients with mitochondrial
diabetes, which indicated that telomere length shorten-
ing likely participates in the pathogenesis of mitochon-
drial diabetes; however, when compared with type 2
diabetes, there was no significant difference; thus, telo-
mere length is not specific to mitochondrial diabetes.
This study investigated the correlation between telomere
length, peak height G to A ratio, and blood glucose con-
dition and noted that there was no significant difference
between these variables. These observations suggest that
telomere length is affected by many factors (higher BMI
[26]) other than ROS; however, we cannot rule out the
impact of the small sample size in the present study.
In this study, the number of patients with mitochon-
drial diabetes using insulin and oral hypoglycemic medi-
cations is equal, but the five probands all received
insulin treatment at the very beginning of diabetes,
which indicated worse beta cell function. An energy me-
tabolism disorder exists in mitochondrial diabetes and is
usually accompanied by elevated blood lactate levels;
thus, to avoid lactic acidosis, oral hypoglycemic medica-
tions, such as metformin, should not be used [26]. In
view of this risk, it is important to differentiate mito-
chondrial diabetes from type 1 or type 2 diabetes.
Table 5 m.3243A>G mitochondrial DNA mutation the peak
height G to A ratio among different ages at onset of
mitochondrial diabetes
Age of onset (year) (n = 15) ≤25 (n = 5) 25–45 (n = 6) >45 (n = 4)
The peak height G to A
ratio
61.60 ± 20.17** 16.59 ± 8.64** 6.37 ± 0.59**
**p < 0.01. There was a significant difference among different ages at onset of
mitochondrial diabetes
Table 6 Correlation analysis between leukocyte telomere length
and FBG, HbA1c, fasting C-peptide, fasting insulin, HOMA-IR index
and HOMA-IS index, and the peak height G to A ratio
Correlation coefficient r P
Fasting blood glucose 0.282 0.374
HbA1c 0.014 0.965
Fasting C-peptide 0.332 0.292
Fasting insulin 0.243 0.463
HOMA-IR −0.127 0.694
HOMA-IS 0.253 0.427
the peak height G to A ratio −0.156 0.646
All data were analyzed after correction for age and duration of disease. All
data were analyzed using Pearson correlation analysis
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Conclusion
Deafness with definite maternal inheritance, normal
BMI, and elevated blood lactic acid and encephalomyop-
athy, for the most part, suggests the diagnosis of mito-
chondrial diabetes. According to Sanger sequencing, the
peak height G/A ratio could reflect the spectrum of age
at the onset of the disease and might therefore provide a
prediction regarding the age of onset in particular cases.
Telomere length was shorter in mitochondrial diabetes
and type 2 diabetes, which suggests that telomere length
shortening is likely involved in the pathogenesis of dia-
betes; however, it was not specific for mitochondrial dia-
betes. Our study also had some limitations, the study
included very limited patient population and the hetero-
plasmy levels were detected in blood instead of urine.
Therefore, in future, further, larger and better designed
studies focused on the topic are still needed to draw
more definitive conclusions.
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